Efficacy of nivolumab/ipilimumab as first-line treatment of pleural mesothelioma in the German real-world setting

被引：0

作者：

Shah, Rajiv

Reck, Martin

Grohe, Christian

Christoph, Daniel Christian

Buchmeier, Eva Lotte

Saalfeld, Felix Carl

Frost, Nikolaj

Kopp, Hans-Georg

Faehling, Martin

Griesinger, Frank

Roeper, Julia

Hoffknecht, Petra

Kuon, Jonas

Luan, Jingting

Chesi, Paolo

Christopoulos, Petros

Thomas, Michael

机构：

[1] Heidelberg Univ Hosp, Dept Thorac Oncol, Heidelberg, Germany

[2] NCT Heidelberg, Natl Ctr Tumor Dis, Heidelberg, Germany

[3] TLRC H, Heidelberg, Germany

[4] German Ctr Lung Res, Heidelberg, Germany

[5] German Ctr Lung Res DZL, Lungen Clin Grosshansdorf, Airway Res Ctr North ARCN, Grosshansdorf, Germany

[6] Evangel Lungenklin Berlin, Klin Pneumol, Berlin, Germany

[7] Evang Kliniken Essen Mitte, Dept Med Oncol, Essen, Germany

[8] Klinikum Stadt Koln gGmbH, Cologne, Germany

[9] Univ Hosp Dresden, Clin Internal Med 1, Dresden, Germany

[10] Charite Univ Med Berlin, Berlin, Germany

[11] Free Univ Berlin, Berlin, Germany

[12] Humboldt Univ, Berlin, Germany

[13] Berlin Inst Hlth, Berlin, Germany

[14] Klin Schillerhohe, Robert Bosch Ctr Tumorerkrankungen, Stuttgart, Germany

[15] Klinikum Esslingen GmbH, Dept Pneumol, Esslingen, Germany

[16] Univ Med Oldenburg, Univ Dept Internal Med Oncol, Pius Hosp, Dept Hematol & Oncol, Oldenburg, Germany

[17] Univ Klin Innere Med Onkol, PIUS Hosp Oldenburg, Oldenburg, Germany

[18] Franziskus Hosp Harderberg, Dept Oncol, Niels Stensen Kliniken, Georgsmarienhutte, Germany

[19] SLK Fachklin Lowenstein, Lowenstein, Germany

[20] Sapienza Univ Rome, Dept Med Oncol, Policlin Umberto 1, Rome, Italy

来源：

JOURNAL OF CLINICAL ONCOLOGY | 2024年 / 42卷 / 16期

关键词：

D O I：

暂无

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

8085

引用

页数：1

共 50 条

[21] Ipilimumab-nivolumab as first-line treatment in metastatic NSCLC
El-Ghazzi, Nathan
Lavaud, Pernelle
BULLETIN DU CANCER, 2021, 108 (03) : 231 - 233
[22] Real-world use of nivolumab plus ipilimumab in the management of diffuse pleural mesothelioma (DPM): experience from the county of Kent
Shanmugalingam, Thurkaa
Kashyap, Vaishnavi
Myers, Andrew
Shah, Riyaz
LUNG CANCER, 2023, 178 : S20 - S20
[23] Immunotherapy Toxicities in Real-World Use of Nivolumab & Ipilimumab in Pleural Malignant Mesothelioma: Experience from Sussex Cancer Centre
Lonn, Cheung
Zaki, Kam
Donovan, Victoria
Kanlal, Kavita
LUNG CANCER, 2024, 190
[24] First-line nivolumab plus ipilimumab versus chemotherapy for the treatment of unresectable malignant pleural mesothelioma: patient-reported outcomes in CheckMate 743
Scherpereel, Arnaud
Antonia, Scott
Bautista, Yolanda
Grossi, Francesco
Kowalski, Dariusz
Zalcman, Gerard
Nowak, Anna K.
Fujimoto, Nobukazu
Peters, Solange
Tsao, Anne S.
Mansfield, Aaron S.
Popat, Sanjay
Sun, Xiaowu
Lawrance, Rachael
Zhang, Xiaoqing
Daumont, Melinda J.
Bennett, Bryan
McKenna, Mike
Baas, Paul
LUNG CANCER, 2022, 167 : 8 - 16
[25] Real-World Outcomes in Patients With Metastatic Renal Cell Carcinoma Treated With First-Line Nivolumab Plus Ipilimumab in the United States
Doshi, Gurjyot K.
Osterland, Andrew J.
Shi, Ping
Yim, Annette
Del Tejo, Viviana
Guttenplan, Sarah B.
Eiffert, Samantha
Yin, Xin
Rosenblatt, Lisa
Conkling, Paul R.
JCO CLINICAL CANCER INFORMATICS, 2024, 8
[26] Nivolumab Plus Ipilimumab Should Be the Standard of Care for First-Line Unresectable Epithelioid Mesothelioma
Baas, Paul
JOURNAL OF THORACIC ONCOLOGY, 2022, 17 (01) : 30 - 33
[27] Real-World Survival Outcomes of Patients with Malignant Pleural Mesothelioma by Physician's Choice of First-line Platinum Chemotherapy
Kerrigan, K.
Chipman, J.
Jo, Y. J.
Haaland, B.
Johnson, E.
Puri, S.
Varghese, T.
Akerley, W.
Patel, S.
JOURNAL OF THORACIC ONCOLOGY, 2021, 16 (03) : S122 - S123
[28] Real-world efficacy of sequential nivolumab for metastatic renal cancer after first-line molecular targeting therapy
Obinata, Daisuke
Funakoshi, Daigo
Sakurai, Fuminori
Yoshizawa, Tsuyoshi
Mochida, Junichi
Yamaguchi, Kenya
Takahashi, Satoru
MEDICINE, 2022, 101 (32) : E29510
[29] Avelumab/Axitinib versus Ipilimumab/Nivolumab: a Kent Oncology Centre Real-world Experience of First-line Combination Treatment for Metastatic Renal Cell Carcinoma
Fenton, M.
Bianchini, D.
Brulinski, P.
CLINICAL ONCOLOGY, 2023, 35 (02) : E237 - E237
[30] First-line treatment outcomes of CML patients in a real-world data setting in Lebanon.
Nasr, Fadi
Yehia, Intissar
El Khoury, Reem
Diab, Saada
Ghoche, Ahmad
Nasr, Lewis
JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)

← 1 2 3 4 5 →